Skip Navigation Links
Skip Navigation Links

Metastatic/Recurrent Breast Cancer

Metastatic Breast Cancer Trails in St. Louis, MO

MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma. EAY131 (NCT02465050)  (MBMC Contact: Henry Robinson 314-996-5865) 

Randomized Phase III trial of mematine and whole-brain radiotherapy with or without hippocampal avoidance in patients with brain metastases  NRG-CC001 (NCT02360215 )  (MBMC Contact:  Diana Christian 314-996-5888)  (Requires radiation oncologist to undergo training and specialized MRIs - approved at MBMC)

Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (Entinostat/Placebo Provided) (measurable disease only)
ECOG E2112 (NCT02115282) 
(MBMC Contact: )

A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer  (Eribulin Provided)  RU0112011/EISAI (NCT02037529)  (MBMC Contact: )  (AVAILABLE ONLY AT MBMC)


A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer  NRG-BR002 (NCT 02364557)  (MBMC Contact:  Henry Robinson 314-996-5865)

Phase II randomized placebo-controled trial of cisplatin with or without ABT-888 (veliparib) in metastatic triple-negative breast cancer and/or BRCA mutation-associated breast cancer  S1416 (NCT02595905) (MBMC Contact:  Henry Robinson 314-996-5865)








All contents 2007 Heartland Cancer Research St. Louis, MO. All rights reserved. Privacy Policy